# US 2022/0009894 A1 · 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009894 A1
- Document ID: US20220009894A1
- Status: Published application
- Kind: A1
- Application number: 17/289,709
- Filed: 2019-09-12
- Published: 2022-01-13
- Earliest claimed: 2019-01-23
- Assignees: Abbisko Therapeutics Co., Ltd.
- Applicants: Abbisko Therapeutics Co., Ltd.
- Inventors: Baowei ZHAO; Guoliang XUN; Yuan ZHAO; Tao FENG; Hongping YU; Zhui CHEN; Yaochang XU
- Web page: https://patentgrep.com/patent/US20220009894A1

## CPC

- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 241/50: with hetero atoms directly attached to ring nitrogen atoms
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/499: Spiro-condensed pyrazines or piperazines
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/542: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/052: the oxygen-containing ring being six-membered
- C07D 497/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A 1,2,3,4-tetrahydroquinoxaline derivative having a structure as represented by formula (I), preparation method therefor and application thereof. These compounds can be widely applied to preparation of drugs for treating one or more tumors, cancers, metabolic diseases, autoimmune diseases or disorders, and a new generation of RORγt agonist drugs is expected to be developed.

## Claims

### Claim 1

A compound of formula (I), a stereoisomer, prodrug or pharmaceutically acceptable salt thereof:
wherein,
L is selected from the group consisting of a bond, —C(R7)═C(R8)—, —(CR9R10)m1—, —(CR11R12)m2—O—, —O—(CR13R14)m3—, —N(R15)—C(O)—, —C(O)—N(R6)—, —(CR17R18)m4—N(R19)—, —N(R20)—(CR21R22)m5—, —(CR23R24)m6—S(O)r— and —S(O)r—(CR25R26)m7—;
ring A is
ring B is
wherein Y is —O— or —N(R27)—;
R1 is selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C1-10 haloalkyl, C1-10 deuterioalkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, ═O, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30;
R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30, or R2 and R3, together with the carbon atom directly attached thereto, form C(O), 3-10 membered cycloalkyl or 3-10 membered heterocyclyl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 haloalkyl, C1-10 deuterioalkyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, ═O, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30;
R4 is selected from the group consisting of hydrogen, deuterium, hydroxy, C1-4 alkyl, vinyl, propenyl, allyl, ethynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, phenyl, benzyl, diazole, triazole, methylsulfonyl, isopropylsulfonyl, aminosulfonyl, carboxyl, methoxycarbonyl, ethoxycarbonyl and acetyl, said C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, phenyl, benzyl, diazole and triazole are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteriomethyl, cyclopropyl, oxacyclobutyl, ═O, methoxy, carboxyl, methoxycarbonyl, acetyl, amino, dimethylamino and acetylamino,
or R4 and R3, together with the carbon atom directly attached thereto, form 5-10 membered heterocyclyl, the 5-10 membered heterocyclyl is unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 haloalkyl, C1-10 deuterioalkyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, ═O, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—C(S)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 haloalkyl, C1-10 deuterioalkyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, ═O, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—C(S)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30;
each R5 is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, —SF5, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 haloalkyl, C1-10 deuterioalkyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, ═O, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30;
each R6 is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 haloalkyl, C1-10 deuterioalkyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, ═O, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30;
R7 and R8 are each independently selected from the group consisting of hydrogen, deuterium, fluorine, C1-4 alkyl, C1-4 deuterioalkyl and C1-4 fluoroalkyl;
R9, R10, R11, R12, R13, R14, R17, R18, R21, R22, R23, R24, R25 and R26 are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30, or R9 and R10, R11 and R12, R13 and R14, R17 and R18, R21 and R22, R23 and R24, R25 and R26, together with the carbon atom directly attached thereto, each independently form C(O), 3-6 membered cycloalkyl, 3-6 membered heterocyclyl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 haloalkyl, C1-10 deuterioalkyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, ═O, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30;
R15, R16, R19, R20 and R27 are each independently selected from the group consisting of hydrogen, deuterium, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, —C0-8—S(O)rR28, —C0-8—C(O)OR29 and —C0-8—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-10 haloalkyl, C1-10 deuterioalkyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, ═O, —C0-8—S(O)rR28, —C0-8—O—R29, —C0-8—C(O)OR29, —C0-8—C(O)R30, —C0-8—O—C(O)R30, —C0-8—NR31R32, —C0-8—C(O)NR31R32 and —C0-8—N(R31)—C(O)R30;
each R28 is independently selected from the group consisting of hydrogen, deuterium, hydroxy, C1-10 alkyl, C1-10 alkoxy, C2-10 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C5-10 aryl, C5-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and —NR31R32, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C5-10 aryl, C5-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and —NR31R32;
each R29 is independently selected from the group consisting of hydrogen, deuterium, C1-10 alkyl, C2-10 alkenyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl and 5-10 membered heteroaryl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, cyano, C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C5-10 aryl, C5-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and —NR31R32;
each R30 is independently selected from the group consisting of hydrogen, deuterium, hydroxy, C1-10 alkyl, C1-10 alkoxy, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C5-10 aryl, C5-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and —NR31R32, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, cyano, C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C5-10 aryl, C5-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and —NR31R32;
each R31 and each R32 are independently selected from the group consisting of hydrogen, deuterium, hydroxy, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, 3-10 membered heterocyclyl, C5-10 aryl, 5-10 membered heteroaryl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, amino, monoalkylamino, dialkylamino and C1-10 alkanoyl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, carboxyl, C1-8 alkyl, C1-10 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C5-10 aryl, C5-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, monoalkylamino, dialkylamino and C1-10 alkanoyl;
or R31 and R32, together with nitrogen atom directly attached thereto, form 4-10 membered heterocyclyl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl, C3-10 cycloalkyloxy, 3-10 membered heterocyclyl, 3-10 membered heterocyclyloxy, C5-10 aryl, C5-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, monoalkylamino, dialkylamino and C1-10 alkanoyl;
m is an integer of 0 to 5; n is an integer of 0 to 3; p is an integer of 0 to 5;
m1, m3, m5 and m7 are each independently 1 or 2;
m2, m4 and m6 are each independently 0, 1 or 2;
each r is independently 0, 1 or 2.

### Claim 2 (depends on 1)

The compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1, wherein,
each R6 is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—O—C(O)R30, —C0-4—NR31R32, —C0-4—C(O)NR31R32 and —C0-4—N(R31)—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, ═O, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—O—C(O)R30, —C0-4—NR31R32, —C0-4—C(O)NR31R32 and —C0-4—N(R31)—C(O)R30; R28, R29, R30, R31 and R32 are defined as in claim 1.

### Claim 3 (depends on 1)

The compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1, wherein, the compound of formula (I) is a compound having formula (IIa):
wherein, R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—O—C(O)R30, —C0-4—NR31R32, —C0-4—C(O)NR31R32 and —C0-4—N(R31)—C(O)R30, or R2 and R3, together with the carbon atom directly attached thereto, form C(O), 3-10 membered cycloalkyl or 3-10 membered heterocyclyl;
R4 is selected from the group consisting of hydrogen, deuterium, hydroxy, C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, phenyl, methylsulfonyl, isopropylsulfonyl, aminosulfonyl, carboxy, methoxycarbonyl, ethoxycarbonyl and acetyl, and said C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl and phenyl are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, cyclopropyl, oxacyclobutyl, methoxy, carboxy, methoxycarbonyl, acetyl, amino, dimethylamino and acetylamino;
ring A, ring B, L, R1, R5, R28, R29, R30, R31, R32, r, m and p are defined as in claim 1.

### Claim 4 (depends on 3)

The compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 3, wherein, the compound of formula (I) is a compound having formula (IIIa1), formula (IIIa2), formula (IIIa3) or formula (IIIa4):
wherein R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30 and —C0-4—O—C(O)R30, or R2 and R3, together with the carbon atom directly attached thereto, form C(O), 3-6 membered cycloalkyl or 3-6 membered heterocyclyl;
R4 is selected from the group consisting of hydrogen, deuterium, C1-4 alkyl, C3-6 cycloalkyl and 3-6 membered heterocyclyl, said C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, cyclopropyl, oxacyclobutyl, methoxy, carboxy, methoxycarbonyl, acetyl, amino, dimethylamino and acetylamino;
each R5 is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl and —O—R29, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, oxacyclobutyl, ═O, methoxy and carboxy;
R7 is selected from the group consisting of hydrogen, deuterium, fluoro, methyl, ethyl, trifluoromethyl, difluoromethyl, trideuteromethyl and dideuteromethyl;
ring A, R1, R29, R30 and m are defined as in claim 3.

### Claim 5 (depends on 1)

The compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1, wherein, the compound of formula (I) is a compound having formula (IIb):
wherein Z is selected from the group consisting of a bond, —O—, —S—, —S(O)—, —S(O)2—, —N(R33)— and —(CR35R36)—;
R33 is selected from the group consisting of hydrogen, deuterium, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—C(S)R30, —C0-4—O—C(O)R30 and —C0-4—C(O)NR31R32, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, ═O, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—C(S)R30, —C0-4—O—C(O)R30 and —C0-4—C(O)NR31R32;
each R34 is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—O—C(O)R30, —C0-4—NR31R32, —C0-4—C(O)NR31R32 and —C0-4—N(R31)—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, ═O, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—O—C(O)R30, —C0-4—NR31R32, —C0-4—C(O)NR31R32 and —C0-4—N(R31)—C(O)R30;
R35 is selected from the group consisting of hydrogen, deuterium, halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—C(S)R30 and —C0-4—O—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, ═O, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—O—C(O)R30, —C0-4—NR31R32, —C0-4—C(O)NR31R32 and —C0-4—N(R31)—C(O)R30;
R36 is selected from the group consisting of hydrogen, deuterium, halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—C(S)R30 and —C0-4—O—C(O)R30, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl, ═O, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—O—C(O)R30, —C0-4—NR31R32, —C0-4—C(O)NR31R32 and —C0-4—N(R31)—C(O)R30;
q is an integer of 0 to 4; ring A, ring B, L, R1, R2, R5, R6, R28, R29, R30, R31, R32, m, r and p are defined as in claim 1.

### Claim 6 (depends on 5)

The compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 5, wherein, the compound of formula (I) is a compound having formula (IIIb1), formula (IIIb2), formula (IIIb3), formula (IIIb4) or formula (IIIb5):
wherein Z is selected from the group consisting of a bond, —O—, —S—, —S(O)—, —S(O)2—, —N(R33)— and —(CR35R36)—;
each R5 is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl and —O—R29, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, oxacyclobutyl, ═O, methoxy and carboxy;
R7 is selected from the group consisting of hydrogen, deuterium, fluoro, methyl, ethyl, trifluoromethyl, difluoromethyl, trideuteromethyl and dideuteromethyl;
R33 is selected from the group consisting of hydrogen, deuterium, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—C(S)R30, —C0-4—O—C(O)R30 and —C0-4—C(O)NR31R32, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, ═O, —C0-4—S(O)rR28, —C0-4—O—R29, —C0-4—C(O)OR29, —C0-4—C(O)R30, —C0-4—O—C(O)R30 and —C0-4—C(O)NR31R32;
R35 is selected from the group consisting of hydrogen, deuterium, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, —O—R29, —C(O)OR29, —O—C(O)R30 and —C(O)NR31R32, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, nitro, azido, C1-4 alkyl, C1-4 haloalkyl, C1-4 deuterioalkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, ═O, —S(O)rR28, —C0-4—O—R29, —C(O)OR29, —C(O)R30 and —C(O)NR31R32;
R36 is selected from the group consisting of hydrogen, deuterium, halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, C1-4 deuterioalkyl and C3-6 cycloalkyl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, nitro, azido, methyl, ethyl, hydroxy, methoxy and carboxy;
ring A, R1, R28, R29, R30, R31, R32 and m are defined as in claim 5.

### Claim 7 (depends on 1)

The compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1, wherein ring A, together with —(R1)m, forms the structure as follows:
wherein each R1 is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl and —O—R29, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, fluoro, chloro, cyano, methyl, ethyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, oxacyclobutyl, ═O, methoxy, carboxy, methoxycarbonyl, acetyl, amino, dimethylamino and acetylamino;
each R28 is independently selected from the group consisting of hydrogen, deuterium, C1-4 alkyl, C2-4 alkenyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C5-8 aryl, 5-8 membered heteroaryl and —NR31R32, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, cyano, C1-4 alkyl, C1-4 alkoxy, C3-8 cycloalkyl, C3-8 cycloalkoxy and 3-8 membered heterocyclyl;
each R29 is independently selected from the group consisting of hydrogen, deuterium, C1-4 alkyl, C2-4 alkenyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C5-8 aryl and 5-8 membered heteroaryl, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, cyano, C1-4 alkyl, C1-4 alkoxy, C3-8 cycloalkyl, C3-8 cycloalkoxy and 3-8 membered heterocyclyl;
each R30 is independently selected from the group consisting of hydrogen, deuterium, hydroxy, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkyloxy, 3-8 membered heterocyclyl, 3-8 membered heterocyclyloxy, C5-8 aryl, C5-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and —NR31R32, above groups are unsubstituted or substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, cyano, C1-4 alkyl, C1-4 alkoxy, C3-8 cycloalkyl, C3-8 cycloalkyloxy, 3-8 membered heterocyclyl, 3-8 membered heterocyclyloxy, C5-8 aryl, C5-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and —NR31R32;
each R31 and each R32 are independently selected from the group consisting of hydrogen, deuterium, hydroxy, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, amino, monoalkylamino and dialkylamino.

### Claim 8 (depends on 1)

The compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1, wherein, the compound is selected from the following compounds:

### Claim 9 (depends on 1)

A preparation method for the compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1, comprising the following step:
optionally, the compound of formula (I) can be obtained by further substitution reaction according to the definitions of substituents R2, R3 and R4;
wherein ring A, ring B, L, R1, R2, R3, R4, R5, R6, m, n and p are defined as in claim 1.

### Claim 10 (depends on 1)

A pharmaceutical composition, comprising the compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1, and pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

A method of preparing medicaments for the treatment of one or more tumors, cancers, metabolic diseases, and autoimmune diseases or disorders comprising using the compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the metabolic disease, and autoimmune disease or disorder are selected from the group consisting of atopic dermatitis, contact dermatitis, allergic dermatitis, comedo, acne, cystic fibrosis, allograft rejection, multiple sclerosis, scleroderma, Systemic Lupus Erythematosus (SLE), psoriasis, Hashimoto's disease, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Psoriatic Arthritis (PsA), autoimmune diabetes, diabetes mellitus type I, diabetes mellitus type II, obesity, fatty liver, adipose tissue-related inflammation, pancreatitis, thyroiditis, autoimmune thyroid disease, biliary cirrhosis, liver fibrosis, Non-alcoholic Fatty Liver Disease (NAFLD), ulcerative colitis, Crohn's disease, regional enteritis, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Syndrome (IBS), Jogging Syndrome (S Jogging Syndrome), original sclerosing cholangitis, autoimmune polyendocrine syndrome type I, autoimmune polyendocrine syndrome type II, celiac disease, neuritis, systemic sclerosis, endometriosis, Behcet's syndrome, myocarditis, dermatomyositis, polymyositis, graft-versus-host disease, sarcoidosis, myocardial infarction, pulmonary hypertension, cutaneous leishmaniasis, Crohn's disease, autoimmune ocular disease, optic neuritis, neuromyelitis optica, xerophthalmia, uveitis, insulin resistance, myasthenia gravis, age-related macular degeneration, Guillain-Barre syndrome, glomerulonephritis, scleritis, major depressive disorder, seasonal affective disorder, Post-Traumatic Stress (Mental) Disorder (PTSD), bipolar disorder, autism, epilepsy, Alzheimer's disease, asthma, Chronic Obstructive Pulmonary Disease (COPD), bronchitis, allergic rhinitis, anaphylactic rhinitis, steroid-resistant asthma, toxic diffuse goiter, Obstructive Sleep Apnea Syndrome (OSAS), sinus polyps and a central nervous system disorder associated with changes in sleep and/or circadian rhythm.

### Claim 13 (depends on 11)

The method of claim 11, wherein the tumor or cancer is selected from the group consisting of fallopian tube tumor, ovarian tumor, peritoneal tumor, stage IV melanoma, solid tumor, glioma, glioblastoma, papillary renal carcinoma, head and neck tumor, lymphoma, myeloma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, synovial sarcoma, hepatocellular carcinoma, breast cancer, uterine cancer, colon cancer, lung cancer, gastric cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, renal cancer, ovarian cancer, bladder cancer, liver cancer, leukemia and non-small cell lung cancer.

### Claim 14 (depends on 1)

The compound of formula (I), the stereoisomer, prodrug or pharmaceutically acceptable salt thereof of claim 1 for use as medicaments for treating one or more tumors, cancers, metabolic diseases, autoimmune diseases or disorders.
